Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: QDEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.67
1 Year Target Price $37.67
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.56% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.86B USD | Price to earnings Ratio - | 1Y Target Price 37.67 |
Price to earnings Ratio - | 1Y Target Price 37.67 | ||
Volume (30-day avg) 8 | Beta 0.59 | 52 Weeks Range 19.50 - 49.45 | Updated Date 12/1/2025 |
52 Weeks Range 19.50 - 49.45 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate 0.5 | Actual 0.8 |
Profitability
Profit Margin -43.45% | Operating Margin (TTM) 6.67% |
Management Effectiveness
Return on Assets (TTM) 1.42% | Return on Equity (TTM) -45.17% |
Valuation
Trailing PE - | Forward PE 10.34 | Enterprise Value 4603627619 | Price to Sales(TTM) 0.68 |
Enterprise Value 4603627619 | Price to Sales(TTM) 0.68 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 67931540 | Shares Floating 62634239 |
Shares Outstanding 67931540 | Shares Floating 62634239 | ||
Percent Insiders 0.94 | Percent Institutions 122.94 |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation was founded in 1979 and has evolved into a leading provider of diagnostic healthcare solutions, focusing on point-of-care diagnostics and molecular diagnostic testing.
Core Business Areas
- Diagnostics: Develops, manufactures and markets rapid diagnostic tests and molecular diagnostic solutions for infectious diseases, cardiometabolic diseases, women's health, and gastrointestinal diseases. Instruments also fall into this category.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other executive officers. The organizational structure is typical of a publicly traded company, with functional departments such as R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- Revenue: Declined significantly after 2022.
- Sofia SARS Antigen FIA: A rapid antigen test for the detection of SARS-CoV-2. Market share varies depending on region and competitor landscape; competitors include Abbott (ABT) with BinaxNOW, Roche (RHHBY), and BD (BDX) with Veritor.
- Lyra PCR Assays: Molecular diagnostic assays for detecting infectious diseases. Competitors include Roche (RHHBY), Hologic (HOLX), and Cepheid (Danaher (DHR)).
- Revenue: Ranges based on product demand
Market Dynamics
Industry Overview
The diagnostics industry is driven by factors like aging populations, increasing prevalence of chronic and infectious diseases, technological advancements, and demand for personalized medicine.
Positioning
Quidel is positioned as a key player in the point-of-care diagnostics market, offering a range of rapid and molecular diagnostic solutions. Their competitive advantage lies in their rapid tests and focus on infectious diseases.
Total Addressable Market (TAM)
The global diagnostics market is estimated to be worth hundreds of billions of dollars. Quidel is positioned to capture a share of this market through its focus on point-of-care testing and molecular diagnostics.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in point-of-care diagnostics
- Established distribution network
- Innovative product pipeline
- Rapid test development capabilities
- High-growth potential in infectious disease diagnostics
Weaknesses
- Reliance on a few key products
- Exposure to seasonality and pandemic fluctuations
- Competitive pricing pressures
- Supply chain vulnerabilities
- Dependence on regulatory approvals
Opportunities
- Expanding product portfolio through acquisitions
- Entering new geographic markets
- Developing innovative diagnostic solutions for emerging diseases
- Leveraging telehealth and digital health technologies
- Growing demand for point-of-care testing
Threats
- Increased competition from larger diagnostic companies
- Regulatory changes and reimbursement pressures
- Technological obsolescence
- Economic downturns
- Emergence of new infectious diseases with unknown diagnostic needs
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
- Becton, Dickinson and Company (BDX)
- Hologic (HOLX)
- Danaher (DHR)
Competitive Landscape
Quidel faces strong competition from larger, more diversified diagnostic companies. Quidel's advantage lies in its focused expertise in rapid testing and infectious disease diagnostics.
Major Acquisitions
Ortho Clinical Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 6000
- Strategic Rationale: The merger with Ortho Clinical Diagnostics expanded Quidel's product portfolio and global reach in the diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the demand for rapid diagnostic tests, particularly during the COVID-19 pandemic.
Future Projections: Future growth is projected to be driven by new product launches, market expansion, and increased adoption of point-of-care testing.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand the product portfolio and geographical reach.
Summary
Quidel, now QuidelOrtho after acquiring Ortho Clinical Diagnostics, faces a challenging market landscape. The company's strength lies in its expanded product offerings and global reach, yet it must navigate increased competition and changing market dynamics. It has the potential to capitalize on growth opportunities in point-of-care testing and diagnostics but is vulnerable to new testing requirements and regulations. Recent mergers and acquisitions will greatly determine its long-term financial health and position in the industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Various Financial Databases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and readers should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.